Premium
Inhibition of tumor cell growth in vitro and in vivo by 2‐methyl 9‐hydroxyellipticinium entrapped within phospholipid vesicles
Author(s) -
Sautereau A. M.,
Cros S.,
Tocanne J. F.
Publication year - 1986
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510070406
Subject(s) - in vivo , l1210 cells , in vitro , chemistry , liposome , phospholipid , vesicle , cytotoxicity , cytotoxic t cell , pharmacology , leukemia , biochemistry , biophysics , biology , membrane , immunology , microbiology and biotechnology
Abstract Encapsulation in liposomes of the antitumoral drug 2‐methyl 9‐hydroxyellipticinium and the consequences of its cytoxicity in vitro on L1210 leukemia cells and on its antitumoral activity in vivo on leukemic mice inoculated with L1210 cells are described. Provided the drugs is dissolved in the buffer below its critical micelle concentration (10 −4 M), it can be encapsulated in lipid vesicles with a very good yield in the form of a very stable combination with the lipids. The in vitro experiments show that 2‐CH 3 9‐OH‐ellipticinium is less cytotoxic against L1210 cells when entrapped than when free in solution. The in vivo experiments on tumor‐bearing mice show that encapsulation of the drug reduces its toxicity. Encapsulation maintains the antitumoral activity of the drug or increases it if the leukemia is delayed (10 4 cells injected per mouse instead of 10 5 cells per mouse).